Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China – GlobeNewswire (press release)
|
Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
GlobeNewswire (press release) CAMBRIDGE, Mass., June 19, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, today announced that China's … Insider Selling: CRISPR THERAPTC (CRSP) CEO Sells 50000 Shares of Stock CRISPR Therapeutics AG (:CRSP) Shares Tick 1.44% For the Week Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.49 Per Share |
